As per notification vide GSR No.332 (E) Dated 23 May 2013 Government had suspended the manufacture, sale and distribution of Dextropropoxyphene and formulations containing Dextropropoxyphene for human use.
Its sale already banned in the US, UK and other countries earlier.
Product permissions granted to the manufacturers and its loan licensees to manufacture this drug and its formulations also stand suspended.
The drug must be withdrawn from the market immediately as per notification of Government of India.
Introduction Looking for Cosmetic Label Compliance India? Are you a cosmetic manufacturer or importer navigating the complex world of Indian regulations? Ensuring your product labels comply with the l..
Summary Short Description Strict regulatory protocols govern clinical investigations for medical devices. Central to this process are forms MD-22 and MD-23. Form MD-22 is an application to Central Lic..
Navigating Software as a Medical Device regulation involves addressing varying global standards, including risk-based classifications...
